J. Rasenack

6.5k total citations · 2 hit papers
71 papers, 4.9k citations indexed

About

J. Rasenack is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, J. Rasenack has authored 71 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hepatology, 37 papers in Epidemiology and 9 papers in Rheumatology. Recurrent topics in J. Rasenack's work include Hepatitis C virus research (50 papers), Hepatitis B Virus Studies (29 papers) and Liver Disease Diagnosis and Treatment (26 papers). J. Rasenack is often cited by papers focused on Hepatitis C virus research (50 papers), Hepatitis B Virus Studies (29 papers) and Liver Disease Diagnosis and Treatment (26 papers). J. Rasenack collaborates with scholars based in Germany, United States and Switzerland. J. Rasenack's co-authors include Stefan Zeuzem, Edward Gane, Sanaa M. Kamal, Amy Lin, M. Diago, S.V. Feinman, E. Jenny Heathcote, Thomas Peters, Joseph H. Hoffman and Michael J. Brunda and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

J. Rasenack

69 papers receiving 4.7k citations

Hit Papers

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C 2000 2026 2008 2017 2000 2007 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
    2000 954 citations Stefan Zeuzem, J. Rasenack et al. profile →
  2. Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
    2007 578 citations Edward Gane, Yun‐Fan Liaw et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Rasenack Germany 32 3.8k 3.6k 400 361 323 71 4.9k
Jean‐Pierre Zarski France 36 4.1k 1.1× 4.1k 1.1× 505 1.3× 310 0.9× 225 0.7× 144 5.3k
Martin Lagging Sweden 32 3.2k 0.8× 2.8k 0.8× 528 1.3× 390 1.1× 363 1.1× 116 4.1k
Andrea D. Branch United States 35 2.0k 0.5× 1.9k 0.5× 327 0.8× 138 0.4× 622 1.9× 127 3.5k
Toshio Shikata Japan 33 2.3k 0.6× 2.1k 0.6× 624 1.6× 303 0.8× 440 1.4× 178 4.0k
Thomas von Hahn Germany 32 2.2k 0.6× 2.0k 0.5× 717 1.8× 351 1.0× 1.0k 3.1× 105 4.5k
Zania Stamataki United Kingdom 26 1.7k 0.4× 1.6k 0.4× 654 1.6× 189 0.5× 515 1.6× 63 3.4k
Jörg Timm Germany 35 2.5k 0.6× 1.9k 0.5× 1.4k 3.5× 206 0.6× 559 1.7× 145 4.7k
Stephanie Noviello United States 20 2.2k 0.6× 2.2k 0.6× 318 0.8× 222 0.6× 359 1.1× 64 2.9k
Tanya Applegate Australia 27 1.5k 0.4× 1.5k 0.4× 468 1.2× 105 0.3× 481 1.5× 117 2.9k
John E. Hegarty Ireland 41 2.1k 0.6× 1.8k 0.5× 187 0.5× 249 0.7× 336 1.0× 106 5.0k

Countries citing papers authored by J. Rasenack

Since Specialization
Citations

This map shows the geographic impact of J. Rasenack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Rasenack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Rasenack more than expected).

Fields of papers citing papers by J. Rasenack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Rasenack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Rasenack. The network helps show where J. Rasenack may publish in the future.

Co-authorship network of co-authors of J. Rasenack

This figure shows the co-authorship network connecting the top 25 collaborators of J. Rasenack. A scholar is included among the top collaborators of J. Rasenack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Rasenack. J. Rasenack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeuzem, Stefan, Edward Gane, Yun‐Fan Liaw, et al.. (2009). Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B. Journal of Hepatology. 51(1). 11–20. 156 indexed citations
2.
Pappas, S. Chris, Lisa M. Nyberg, Susan Greenbloom, et al.. (2006). 734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial. Journal of Hepatology. 44. S271–S271. 23 indexed citations
3.
4.
Berg, Thomas, Michael Wagner, Samer Nasser, et al.. (2006). Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology. 130(4). 1086–1097. 368 indexed citations
5.
Berg, Carl L., Fernando Lopes Gonçales, David Bernstein, et al.. (2006). Re‐treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon‐alpha‐2a (40 kDa) and ribavirin. Journal of Viral Hepatitis. 13(7). 435–440. 27 indexed citations
6.
Kamal, Sanaa M., Jason Chen, J Fehr, et al.. (2006). Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology. 43(5). 923–931. 97 indexed citations
7.
Wagner, Michael, M Huber, Thomas Berg, et al.. (2005). Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. Gastroenterology. 129(2). 522–527. 319 indexed citations
8.
Huber, M, Thomas Berg, Hans‐Harald Hinrichsen, et al.. (2005). Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. Gastroenterology. 129(2). 522–527. 67 indexed citations
9.
Schaefer, Oliver, Christian Lohrmann, Wolfgang Kreisel, et al.. (2005). Differentiation of Perianal Fistulas With Digital Subtraction Magnetic Resonance Fistulography. Inflammatory Bowel Diseases. 11(4). 383–387. 5 indexed citations
10.
Kamal, Sanaa M., Leonardo Bianchi, Margaret James Koziel, et al.. (2001). Specific Cellular Immune Response and Cytokine Patterns in Patients Coinfected with Hepatitis C Virus and Schistosoma mansoni. The Journal of Infectious Diseases. 184(8). 972–982. 51 indexed citations
11.
Kamal, Sanaa M., et al.. (2001). Relation of cytokines to progression of liver fibrosis in chronic hepatitis C. Gastroenterology. 120(5). A552–A552. 4 indexed citations
12.
Kamal, Sanaa M., J. Rasenack, Leonardo Bianchi, et al.. (2001). Acute hepatitis C without and with schistosomiasis: Correlation with hepatitis C–Specific CD4+ T-cell and cytokine response. Gastroenterology. 121(3). 646–656. 113 indexed citations
13.
14.
Andus, Tilo, K. W. Ecker, Andreas Raedler, et al.. (1998). Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. Gut. 42(4). 493–496. 80 indexed citations
15.
Peters, Thomas, et al.. (1997). Quasispecies analysis in hepatitis C virus infection by fluorescent single strand conformation polymorphism. Journal of Virological Methods. 64(1). 95–102. 7 indexed citations
16.
Grotz, W, Thomas Peters, H.‐J. Schlayer, et al.. (1996). Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease. Journal of Molecular Medicine. 74(7). 407–412. 2 indexed citations
17.
Preisler-Adams, Sabine, et al.. (1993). Complete nucleotide sequence of a hepatitis B virus, subtype adw2, and identification of three types of C open reading frame. Nucleic Acids Research. 21(9). 2258–2258. 11 indexed citations
18.
Peters, Thomas, et al.. (1993). Frequency of hepatitis C in acute post‐transfusion hepatitis after open‐heart Surgery: A prospective study in 1,476 patients. Journal of Medical Virology. 39(2). 139–145. 14 indexed citations
19.
Schlayer, H.‐J., et al.. (1992). Cause and frequency of posttransfusion hepatitis after open-heart surgery. Journal of Molecular Medicine. 70(7). 579–84. 4 indexed citations
20.
Rasenack, J. & Wolfgang Kreisel. (1991). [Conservative therapy of ulcerative colitis and Crohn disease].. PubMed. 109(11). 245–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Pierre Zarski Breakdown of academic impact, for papers by Martin Lagging Breakdown of academic impact, for papers by Andrea D. Branch Breakdown of academic impact, for papers by Toshio Shikata Breakdown of academic impact, for papers by Thomas von Hahn Breakdown of academic impact, for papers by Zania Stamataki Breakdown of academic impact, for papers by Jörg Timm Breakdown of academic impact, for papers by Stephanie Noviello Breakdown of academic impact, for papers by Tanya Applegate Breakdown of academic impact, for papers by John E. Hegarty
Rankless by CCL
2026